Private company

Yew Bio-Pharm Group, Inc.

Yew Bio-Pharm Group, Inc. is an American agricultural production-crops company, incorporated in Nevada.¹ It is headquartered in El Monte, California.¹

Last updated Oct 20, 2026.

Overview

IndustryAgricultural Production-Crops¹
HeadquartersEl Monte, California¹
Incorporated inNV²
Business address9460 Telstar Avenue, Suite 6, El Monte, Ca 91731²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

12.9%Gross margin³

9.4%Operating margin³

5.4%Net margin³

-2.1%Revenue growth, 2020³

3.2%Return on equity³

$17.3MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2020

Cost of revenue

Cost of revenue87¢$23.8M
Selling, general and admin4¢$989.0K
Other costs4¢$1.0M
Income tax0¢$28.8K
Profit5¢$1.5M

Out of $27.3M in revenue.³

Where each dollar of operating cash went, fiscal 2020

Kept or used elsewhere

Capital spending0¢$54.9K
Kept or used elsewhere100¢$17.3M

Out of $17.3M of cash from operations.³

Financial statements

Revenue⁴⁵⁶⁷⁸³$27.3M in 2020+253% since 2014

Gross profit⁴⁵⁶⁷⁸³$3.5M in 2020−37% since 2014

Operating income⁴⁵⁶⁷⁸³$2.6M in 2020−40% since 2014

Net income⁴⁵⁶⁷⁸³$1.5M in 2020−66% since 2014

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Revenue	$7.7M⁴	$29.6M⁵	$51.3M⁶	$40.5M⁷	$37.6M⁸	$27.9M³	$27.3M³
Cost of revenue	$2.1M⁴	$22.5M⁵	$48.1M⁶	$35.5M⁷	$26.9M⁸	$27.1M³	$23.8M³
Gross profit	$5.6M⁴	$7.0M⁵	$3.2M⁶	$5.1M⁷	$10.7M⁸	$774.1K³	$3.5M³
Research and development	$53.5K⁴	$13.6K⁵	$860⁶	$0⁷	$0⁸	$0⁸
Selling, general and admin				$1.0M⁷	$1.0M⁸	$1.2M³	$989.0K³
Operating income	$4.3M⁴	$5.1M⁵	$2.1M⁶	$3.3M⁷	$718.6K⁸	$1.0M³	$2.6M³
Income tax		$16.5K⁵	$18.0K⁶	$614⁷	$1.5M⁸	$11.2K³	$28.8K³
Net income	$4.3M⁴	$5.3M⁵	$2.0M⁶	$3.2M⁷	-$1.3M⁸	$985.5K³	$1.5M³
Earnings per share	$0.08⁴	$0.10⁵	$0.04⁶	$0.06⁷	-$0.03⁸	$0.02³	$0.04³
Earnings per share (diluted)	$0.07⁴	$0.10⁵	$0.04⁶	$0.06⁷	-$0.03⁸	$0.02³	$0.04³

Total assets⁴⁵⁶⁷⁸³$58.4M in 2020+67% since 2014

Total liabilities⁴⁵⁶⁷⁸³$13.0M in 2020+9140% since 2014

Shareholders’ equity⁶⁷⁸³$45.5M in 2020+30% since 2014

Cash⁵⁶⁷⁸³$563.8K in 2020+16% since 2014

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Cash	$487.9K⁵	$681.6K⁶	$279.0K⁷	$859.8K⁸	$521.7K⁸	$742.3K³	$563.8K³
Current assets	$3.2M⁴	$16.9M⁵	$33.8M⁶	$35.4M⁷	$12.4M⁸	$11.7M³	$10.0M³
Total assets	$35.0M⁴	$43.8M⁵	$46.2M⁶	$52.9M⁷	$49.7M⁸	$54.2M³	$58.4M³
Current liabilities	$140.3K⁴	$4.6M⁵	$7.5M⁶	$7.4M⁷	$7.1M⁸	$10.5M³	$10.5M³
Total liabilities	$140.3K⁴	$4.6M⁵	$7.6M⁶	$7.8M⁷	$8.6M⁸	$12.8M³	$13.0M³
Shareholders’ equity	$34.9M⁶	$39.2M⁶	$38.6M⁷	$45.2M⁸	$41.1M³	$41.4M³	$45.5M³
Shares outstanding	52.1M shares⁴	51.9M shares⁵	51.9M shares⁶	51.9M shares⁷	52.1M shares⁸	51.7M shares³	51.7M shares³

Cash from operations⁴⁵⁶⁷⁸³$17.3M in 2020+321% since 2014

Capital spending⁴⁵⁶⁸³$54.9K in 2020+544% since 2014

Free cash flow⁴⁵⁶⁸³$17.3M in 2020+321% since 2014

Fiscal year	2014	2015	2016	2017	2018	2019	2020
Cash from operations	$4.1M⁴	-$1.4M⁵	$643.0K⁶	-$2.6M⁷	$32.5M⁸	$12.0M³	$17.3M³
Capital spending	$8.5K⁴	$31.5K⁵	$61.5K⁶		$43.5K⁸	$25.9K³	$54.9K³
Free cash flow	$4.1M	-$1.4M	$581.5K		$32.4M	$11.9M	$17.3M

Compare Yew Bio-Pharm Group, Inc. with another company

What it owns

What Yew Bio-Pharm Group, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Land	$9.8M⁸ Dec 31, 2019	$9.8M⁸ Dec 31, 2018	0%
Property and equipment, before depreciation	$1.8M³ Dec 31, 2020	$1.7M³ Dec 31, 2019	+8.7%
Accumulated depreciation	$1.3M³ Dec 31, 2020	$1.2M³ Dec 31, 2019	+11.0%
Property and equipment, net	$489.2K³ Dec 31, 2020	$474.9K³ Dec 31, 2019	+3.0%
Operating-lease assets (leased space)	$333.4K³ Dec 31, 2020	$399.8K³ Dec 31, 2019	−16.6%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$563.8K³ Dec 31, 2020	$742.3K³ Dec 31, 2019	−24.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Intangible assets, net (excluding goodwill)	$27.7K³ Dec 31, 2020	$32.3K³ Dec 31, 2019	−14.2%
Finite-lived intangibles, gross	$46.3M³ Dec 31, 2020	$44.8M³ Dec 31, 2019	+3.4%
Accumulated amortization	$4.3M³ Dec 31, 2020	$4.7M³ Dec 31, 2019	−8.1%
Finite-lived intangibles, net	$42.0M³ Dec 31, 2020	$40.0M³ Dec 31, 2019	+4.8%

Inventory

Item	Latest	A year before	Change
Inventory, total	$14.6K³ Dec 31, 2020	$2.6M³ Dec 31, 2019	−99.4%

Leadership

Who has led Yew Bio-Pharm Group, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Adam C. Wasserman2012

201520202025

Chief financial officerAdam C. Wasserman Jul 17, 2012 to Jul 17, 2012⁹

Board members and other officers (7)

TreasurerGuifang Qi Jul 17, 2012 to Mar 23, 2015¹⁰
Board memberGuoshuang Tian Sep 29, 2020 to Sep 29, 2020¹¹
Board memberXiefeng Liu Sep 29, 2020 to Sep 29, 2020¹²
Board memberXuehai Wu Sep 29, 2020 to Sep 29, 2020¹³
Board memberYongchun Shi Sep 29, 2020 to Sep 29, 2020¹⁴
Board memberGuifang Qi Jul 17, 2012 to Mar 23, 2015¹⁰
Board memberXingming Han Jul 17, 2012 to Dec 13, 2012¹⁵

Timeline

Mar 29, 20228-K Executive or director change¹⁶

Filings

6 filings to the SEC since October 2021: 1 quarterly reports, 1 major events, 4 other. The latest 6:

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Yew Bio-Pharm Group, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARYew Bio-Pharm Group, Inc.¹
CIK0001548240
Employer ID (EIN)26-1579105¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inNevada¹
Fiscal year endsDecember 31¹
Industry code (SIC)0100 Agricultural Production-Crops¹
Business address9460 Telstar Avenue, Suite 6, El Monte, CA 91731¹
Phone626-401-9588¹
Shares outstanding51,700,000 as of Nov 12, 2021¹⁷
Public float$5.8M as of Jun 30, 2020³
On EDGAR sinceMay 8, 2012¹
Filings152 in all: 8-K (34), 10-Q (29), CORRESP (10), 10-K (9), 3 (8), DEFA14C (8), DEF 14C (7), 4 (6)¹
All 26 form types
PRE 14C (6), UPLOAD (6), NT 10-Q (5), S-1/A (3), 10-12G/A (2), 10-Q/A (2), 3/A (2), DEF 14A (2), EFFECT (2), NT 10-K (2), S-1 (2), 10-12G (1), 424B3 (1), ARS (1), DEFR14C (1), PRE 14A (1), PRER14A (1), REVOKED (1)
Latest filingsAnnual report (10-K) Mar 30, 2021
Quarterly report (10-Q) Nov 15, 2021
Proxy statement (DEF 14A) Apr 30, 2013
Latest 8-K (8-K) Mar 29, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARYew Bio-Pharm Group, Inc. filings on SEC EDGAR
2
SEC EDGARYew Bio-Pharm Group, Inc. filings on SEC EDGAR
3
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2020
4
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2014
5
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2015
6
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2016
7
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2017
8
SEC EDGARYew Bio-Pharm Group, Inc. 10-K for fiscal 2018
9
SEC EDGARAdam C. Wasserman, Chief financial officer
10
SEC EDGARGuifang Qi, Treasurer
11
SEC EDGARGuoshuang Tian, Board member
12
SEC EDGARXiefeng Liu, Board member
13
SEC EDGARXuehai Wu, Board member
14
SEC EDGARYongchun Shi, Board member
15
SEC EDGARXingming Han, Board member
16
SEC EDGARExecutive or director change
17
SEC EDGARYew Bio-Pharm Group, Inc. 10-Q filed Nov 15, 2021: shares outstanding